Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Coherus Oncology (CHRS) Other Gross PP&E Adjustments (2016 - 2025)

Coherus Oncology's Other Gross PP&E Adjustments history spans 13 years, with the latest figure at -$21.0 million for Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments fell 179.17% year-over-year to -$21.0 million; the TTM value through Dec 2025 reached -$21.0 million, down 179.17%, while the annual FY2025 figure was -$21.0 million, 179.17% down from the prior year.
  • Other Gross PP&E Adjustments for Q4 2025 was -$21.0 million at Coherus Oncology, down from -$7.5 million in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at $28.9 million in Q3 2022 and bottomed at -$21.0 million in Q4 2025.
  • The 5-year median for Other Gross PP&E Adjustments is $25.4 million (2021), against an average of $15.6 million.
  • The largest YoY upside for Other Gross PP&E Adjustments was 110.85% in 2021 against a maximum downside of 458.23% in 2021.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at -$7.1 million in 2021, then increased by 12.48% to -$6.2 million in 2022, then tumbled by 68.62% to -$10.5 million in 2023, then grew by 28.59% to -$7.5 million in 2024, then tumbled by 179.17% to -$21.0 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Other Gross PP&E Adjustments are -$21.0 million (Q4 2025), -$7.5 million (Q4 2024), and $23.5 million (Q3 2024).